俊 彦 平野

Dr. 俊 彦 平野


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
WXWencheng Xu
Wencheng Xu
XWXiaoqin Wang
Xiaoqin Wang
YTYuanchao Tu
Yuanchao Tu
HMHiroshi Masaki
Hiroshi Masaki
STSachiko Tanaka
Sachiko Tanaka
俊平俊 彦 平野
俊 彦 平野

1 January 2021 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
WXWencheng Xu
Wencheng Xu
SCShuhe Chen
Shuhe Chen
XWXiaoqin Wang
Xiaoqin Wang
STSachiko Tanaka
Sachiko Tanaka
KOKenji Onda
Kenji Onda
俊平俊 彦 平野
俊 彦 平野

13 August 2018 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
BYBo Yuan
Bo Yuan
MYMingjiang Yao
Mingjiang Yao
XWXiao Wang
Xiao Wang
ASAi Sato
Ai Sato
AOAyane Okazaki
Ayane Okazaki
NTNorio Takagi
Norio Takagi
Triple-negative breast cancer (TNBC) is one of the most difficult subtypes of breast cancer to treat due to its aggressive, metastatic behavior, and a lack of a targeted therapy. Trivalent arsenic derivatives (arsenite, AsIII) with remarkable clinical efficacy in acute promyelocytic leukemia has been demonstrated to exhibit inhibitory effect against breast cancer cells. To provide novel insight into the development of new therapeutic strategies, antitumor activity of AsIII and tetrandrine (Tetra), a Chinese plant-derived alkaloid, against the TNBC cell line MDA-MB-231 in vitro and in vivo was investigated. Cytotoxicity was evaluated using cell viability, lactate dehydrogenase leakage and cell cycle assay. Alterations of genes related to cell proliferation and death were analyzed using western blotting. In vivo antitumor activity of AsIII alone or in combination with Tetra was studied using MDA-MB-231 xenografts in nude mice. Synergistic cytotoxic effects of two drugs were observed in the cells. In vivo study also showed that co-administration of AsIII and Tetra significantly reduced tumor volume and weight, directly supporting its in vitro antitumor activity. No deaths and reduction of body-weight were observed after a long-term co-administration, indicating its good tolerability. S-phase arrest associated with the upregulation of FOXO3a, p27 along with decreased Cyclin D1 expression was observed in the cells treated with the combined regimen. A substantial upregulated p21 expression and downregulated phospho-FOXO3a and Cyclin D1 expression was observed in the tumor tissues of mice co-administered with AsIII and Tetra. Autophagy induction was observed in the combination treatment in vitro and in vivo. The addition of wortmannin, a potent autophagy inhibitor, significantly rescued MDA-MB-231 cells from their cytotoxicity of AsIII and Tetra. S-phase arrest, autophagic and necrotic cell death contribute to the cytocidal effects of the combined regimen of AsIII and Tetra. Considering our previous study showing synergistic cytotoxic effects of the combined regimen in estrogen receptor-positive breast cancer cell line MCF-7, these results suggest that development of the combination regimen of AsIII plus Tetra may offer many benefits to patients with different types of breast cancer.

9 October 2018 in Oncology Reports
Verified
Journal Article
Open access
PDF file
YZYuxue Zhao
Yuxue Zhao
KOKenji Onda
Kenji Onda
KSKentaro Sugiyama
Kentaro Sugiyama
BYBo Yuan
Bo Yuan
STSachiko Tanaka
Sachiko Tanaka
俊平俊 彦 平野
俊 彦 平野
In the present study, the antitumor effects of arsenic disulfide (As2S2) on the proliferative, survival and migratory ability of human breast cancer MCF-7 and MDA-MB-231 cells were investigated, and its potential underlying molecular mechanisms with an emphasis on cell cycle arrest, apoptosis induction, autophagy induction and reactive oxygen species (ROS) generation were determined. The results indicated that As2S2 significantly inhibited the viability, survival and migration of breast cancer cells in a dose-dependent manner. In addition, it was identified that As2S2 induced cell cycle arrest primarily at G(2)/M phase in the two breast cancer cell lines by regulating the expression of associated proteins, including cyclin B1 and cell division cycle protein 2. In addition to cell cycle arrest, As2S2 also triggered the induction of apoptosis in cells by activating the expression of pro-apoptotic proteins, including caspase-7 and -8, as well as increasing the B-cell lymphoma 2 (Bcl-2)-associated X protein/Bcl-2 ratio, while decreasing the protein expression of anti-apoptotic B-cell lymphoma extra-large. In addition, As2S2 stimulated the accumulation of microtubule-associated protein 1A/1B-light chain 3 (LC3)-II and increased the LC3-II/LC3-I ratio, indicating the occurrence of autophagy. As2S2 treatment also inhibited the protein expression of matrix metalloproteinase-9 (MMP-9), but increased the intracellular accumulation of ROS in the two breast cancer cell lines, which may assist in alleviating metastasis and attenuating the progression of breast cancer. Taken together, the results of the present study suggest that As2S2 inhibits the progression of human breast cancer cells through the regulation of cell cycle arrest, intrinsic and extrinsic apoptosis, autophagy, MMP-9 signaling and ROS generation.

1 March 2014 in Life Sciences
Verified
Journal Article
Closed access
HHHiroshige Hatanaka
Hiroshige Hatanaka
HIHitomi Ishizawa
Hitomi Ishizawa
YNYurie Nakamura
Yurie Nakamura
HTHiroko Tadokoro
Hiroko Tadokoro
STSachiko Tanaka
Sachiko Tanaka
俊平俊 彦 平野
俊 彦 平野

1 October 2011 in Journal of Pharmacy and Pharmacology
Verified
Journal Article
Closed access
PDF file
YHYoko Hiwatashi
Yoko Hiwatashi
MMMasaki Maeda
Masaki Maeda
HFHisayo Fukushima
Hisayo Fukushima
KOKenji Onda
Kenji Onda
STSachiko Tanaka
Sachiko Tanaka
俊平俊 彦 平野
俊 彦 平野